title: Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.
abstract: BACKGROUND
  Sitagliptin, a highly selective dipeptidyl peptidase-4 inhibitor, is the first in a new class of oral antihyperglycemic agents (AHAs) for the treatment of patients with type 2 diabetes. Type 2 diabetes is a life-long disease requiring chronic treatment and management. Therefore, robust assessment of the long-term safety and tolerability of newer therapeutic agents is of importance. The purpose of this analysis was to assess the safety and tolerability of sitagliptin by pooling 12 large, double-blind, Phase IIb and III studies up to 2 years in duration.
  
  
  METHODS
  This analysis included 6139 patients with type 2 diabetes receiving either sitagliptin 100 mg/day (N = 3415) or a comparator agent (placebo or an active comparator) (N = 2724; non-exposed group). The 12 studies from which this pooled population was drawn represent the double-blind, randomized, Phase IIB and III studies that included patients treated with the clinical dose of sitagliptin (100 mg/day) for at least 18 weeks up to 2 years and that were available in a single safety database as of November 2007. These 12 studies assessed sitagliptin as monotherapy, initial combination therapy with metformin, or add-on combination therapy with other oral AHAs (metformin, pioglitazone, sulfonylurea, sulfonylurea + metformin, or metformin + rosiglitazone). Patients in the non-exposed group were taking placebo, pioglitazone, metformin, sulfonylurea, sulfonylurea + metformin, or metformin + rosiglitazone. This safety analysis used patient-level data from each study to evaluate clinical and laboratory adverse experiences.
  
  
  RESULTS
  For clinical adverse experiences, the incidence rates of adverse experiences overall, serious adverse experiences, and discontinuations due to adverse experiences were similar in the sitagliptin and non-exposed groups. The incidence rates of specific adverse experiences were also generally similar in the two groups, with the exception of an increased incidence rate of hypoglycemia observed in the non-exposed group. The incidence rates of drug-related adverse experiences overall and discontinuations due to drug-related adverse experiences were higher in the non-exposed group, primarily due to the increased incidence rate of hypoglycemia in this group. For cardiac- and ischemia-related adverse experiences (including serious events), there were no meaningful between-group differences. No meaningful differences between groups in laboratory adverse experiences, either summary measures or specific adverse experiences, were observed.
  
  
  CONCLUSIONS
  In patients with type 2 diabetes, sitagliptin 100 mg/day was well tolerated in clinical trials up to 2 years in duration.
authors.affiliation: Merck Research Laboratories, Rahway, NJ, USA. debora_williamsherman@merck.com
authors.forename: Debora
authors.initials: D
authors.lastname: Williams-Herman
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Round
authors.forename: Arlene S
authors.initials: AS
authors.lastname: Swern
authors.forename: Bret
authors.initials: B
authors.lastname: Musser
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Davies
authors.forename: Peter P
authors.initials: PP
authors.lastname: Stein
authors.forename: Keith D
authors.initials: KD
authors.lastname: Kaufman
authors.forename: John M
authors.initials: JM
authors.lastname: Amatruda